NASDAQ NMS - GLOBAL MARKET · ETON
-2.75% · -$1.57 · Vol 891.7K
Market closed · last close 4:00 PM ET · price as of 17:29:56 ET
Eton Pharmaceuticals Inc

Eton Pharmaceuticals Inc

Pharmaceuticals
$55.50
Card
Relationship Map

Follow $ETON

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $ETON by email

Veridion Score

BETAMEDIUM CONF · 6 of 6 factors measuredMethodology
ETON
Eton Pharmaceuticals Inc
Fri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET
Upper range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

70/ 100
Veridion Score
Upper range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Fri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ETON moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ETON catalysts
About Eton Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2018
Employees
44
Country
US

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$56.97
Day high
$57.49
Day low
$55.41
Previous close
$57.07
52W high
$64.43
-13.86% from high
52W low
$14.35
82% of range
Market cap
$1.6B
P/E
126.14×
EPS
$0.4400
Beta
-0.49
Shares out
28.6M
Volume
891.7K
1.46× rel vol
Avg volume
608.8K
VWAP
$55.71
Price history computed in-house
1W
-2.77%
1M
-12.56%
3M
+69.62%
1Y
+202.62%
YTD
+228.21%
SMA 50 $51.39 · above
SMA 200 $30.11 · above
52W position 82%

ETON overview

Veridion Score
70
Registered · 2026-09-18
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around ETON.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading ETON Form 4 filings
Public disclosures

Congress activity in ETON

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for ETON in the cached public ledger.

Federal contracts

ETON contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ETON in this window.
Lobbying spend

ETON lobbying filings, year to date.

Registered lobbying filings matched to Eton Pharmaceuticals Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ETON in this window.
Loading news for ETON
Analyst ratings
Sovereign unlock shows live analyst consensus for ETON.
Options
Sovereign unlock shows live options positioning for ETON.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.